# Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma

Source: https://onco.cc/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/  
OnCo record `paper-fader-trastuzumab-uterine-serous-jco-2018` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding trastuzumab to chemotherapy for HER2-positive uterine serous carcinoma, an aggressive endometrial cancer, lengthened progression-free survival by about four months and later showed a survival benefit, making HER2 testing routine in this subtype.

## Summary

Randomised phase 2 trial of 61 women with HER2-positive (immunohistochemistry 3+ or amplified) advanced or recurrent uterine serous carcinoma treated with carboplatin-paclitaxel with or without trastuzumab continued as maintenance.

Median progression-free survival was 12.6 versus 8.0 months (hazard ratio 0.44), with the largest gain in newly diagnosed stage III to IV disease (17.9 versus 9.3 months); an update showed improved overall survival in that group.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2018
- DOI: 10.1200/JCO.2017.76.5966
- Authors: Fader AN, Roque DM, Siegel E, et al.
- Findings: Median progression-free survival 12.6 vs 8.0 months; hazard ratio 0.44.; Stage III to IV newly diagnosed: 17.9 vs 9.3 months, with an overall survival benefit on update.
- What it means: HER2 testing of every serous endometrial cancer and trastuzumab with first-line chemotherapy for HER2-positive advanced disease are now guideline recommendations; trastuzumab deruxtecan extends the option.
- Caveats: Small phase 2 trial.; About 30 percent of uterine serous carcinomas are HER2-positive; benefit in lower expression is unknown.

## Sources

- J Clin Oncol 2018: https://doi.org/10.1200/JCO.2017.76.5966
- PubMed: https://pubmed.ncbi.nlm.nih.gov/29584549/

## Connected records

- cancers: [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-fader-trastuzumab-uterine-serous-jco-2018.json